<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396706</url>
  </required_header>
  <id_info>
    <org_study_id>EA-14-01-077</org_study_id>
    <nct_id>NCT02396706</nct_id>
  </id_info>
  <brief_title>RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough</brief_title>
  <official_title>Randomized, Controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of a Liquid Containing Ivy Leaves Dry Extract vs. Placebo in the Treatment of Acute Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Engelhard Arzneimittel GmbH &amp; Co.KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Engelhard Arzneimittel GmbH &amp; Co.KG</source>
  <brief_summary>
    <textblock>
      Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety&#xD;
      of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>whole treatment period over 7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Acute Cough</condition>
  <arm_group>
    <arm_group_label>Ivy Leaves Cough Liquid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivy Leaves Cough Liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivy Leaves Cough Liquid</intervention_name>
    <arm_group_label>Ivy Leaves Cough Liquid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute cough with symptoms lasting 2-3 days prior to treatment&#xD;
&#xD;
          2. Men or women of any ethnic origin&#xD;
&#xD;
          3. Age 18 to 75 years&#xD;
&#xD;
          4. Subjects who are able to understand and are willing to comply to trial instructions&#xD;
&#xD;
          5. Having given written informed consent&#xD;
&#xD;
          6. Satisfactory health except for the cough as determined by the investigator based on&#xD;
             medical history and physical examination&#xD;
&#xD;
          7. CS score of at least 50 mm on a 100 mm VAS at V1&#xD;
&#xD;
          8. Acute BSS of at least 10 points at V1&#xD;
&#xD;
          9. VCD score of at least 2 points at V1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic bronchial asthma, bronchial hyperreactivity, chronic bronchitis, other&#xD;
             chronic or inherited lung disease&#xD;
&#xD;
          2. History of hypersensitivity to any excipient of the applied drugs&#xD;
&#xD;
          3. History of drug hypersensitivity, asthma, urticaria, or other severe allergic&#xD;
             diathesis as well as current hay fever&#xD;
&#xD;
          4. History of chronic gastritis or peptic ulcers&#xD;
&#xD;
          5. Any gastrointestinal complaints within 7 days before V1&#xD;
&#xD;
          6. Participation in a clinical trial within 30 days prior to the treatment phase of this&#xD;
             study or concomitantly&#xD;
&#xD;
          7. Treatment with corticoids, beta-2 agonists (e.g. salbutamol, fenoterol), expectorants,&#xD;
             theophylline, antitussives, anaesthetics, acetylsalicylic acid (e.g. aspirin) or other&#xD;
             non-steroidal anti-inflammatory drugs, leukotriene inhibitors, angiotensin-converting&#xD;
             enzyme (ACE) inhibitors, antiviral drugs or antibiotics, antihistamines,&#xD;
             immunosuppressants, isoprenaline, atropine, sodium cromoglycate or homeopathic drugs&#xD;
             against common cold within 7 days before V1&#xD;
&#xD;
          8. Drug or alcohol abuse in the opinion of the investigator&#xD;
&#xD;
          9. Pregnant or nursing (lactating) women&#xD;
&#xD;
         10. Women of child-bearing potential (defined as all women physiologically capable of&#xD;
             becoming pregnant) who are not using an acceptable method of contraception.&#xD;
&#xD;
         11. Subjects with significant diseases, defined as a disease which, in the opinion of the&#xD;
             investigator, may either put the subject at risk because of participation in the trial&#xD;
             or a disease which may influence the results of the trial or the subject's ability to&#xD;
             participate in the trial; includes subjects with a history of gastrointestinal&#xD;
             bleeding, significant cardiovascular, liver or renal disease.&#xD;
&#xD;
         12. Subjects directly or indirectly involved in the execution of this protocol, including&#xD;
             employees of the CRO and persons related to them.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Schaefer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizentrum Essen-Borbeck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizentrum Essen-Borbeck</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

